A New Parameter Derived From DSA to Evaluate Cerebral Perfusion
Launched by XI'AN NO.3 HOSPITAL · Jul 20, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to measure blood flow to the brain, known as cerebral perfusion, using a technique called digital subtraction angiography (DSA). This research aims to improve our understanding of cerebral ischemia, a condition where the brain doesn't receive enough blood and oxygen, which can lead to serious health issues. The trial is currently looking for participants of all ages who have experienced cerebral ischemia and have already undergone a DSA procedure.
If you or someone you know is considering joining this study, it's important to note that individuals with cerebral hemorrhage (bleeding in the brain) cannot participate. Those who are eligible may have the opportunity to contribute to important research that could help improve future treatments for brain blood flow issues. Participants will be involved in an observational study, which means they will be monitored but not given any new treatments as part of the trial. This is a chance to help advance medical science while being part of a supportive research environment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Cerebral ischemia
- • 2. patients undergone DSA
- Exclusion Criteria:
- • 1.cerebral hemorrhage
About Xi'an No.3 Hospital
Xi'an No. 3 Hospital is a leading medical institution in Xi'an, China, recognized for its commitment to advancing healthcare through innovative research and clinical excellence. With a focus on a wide range of medical specialties, the hospital plays a pivotal role in conducting clinical trials that aim to enhance treatment outcomes and patient care. Its state-of-the-art facilities and a team of experienced healthcare professionals enable the hospital to rigorously evaluate new therapies and interventions, contributing to the global body of medical knowledge and improving health services for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shaanxi, China
Patients applied
Trial Officials
Nannan Han, doctor
Study Director
department of neurology Xi'an No3 Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials